Jasdeep Manik, OD
Optometry · East Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · South County Community Health Center Inc · 20 clinicians in this group
Looking this up.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Manik’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence C14995 · Deceased
Licence status: Deceased · since 1953 · Cornell University Medical College.
Licensee is deceased.
Matched on the licence number without its letter prefix; check the name before relying on it.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Medicaid work
$124,551 in 2024
Medicaid paid $124,551 for 1,454 billed services this clinician did in 2024, up to 65 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Clinic visit/encounter, all-inclusive | 281 | $107,283 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 531 | $11,464 |
| DETERMINATION REFRACTIVE STATE | 507 | $2,740 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 78 | $2,122 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 57 | $942 |
| 2024 | 1,454 | 5 | 65 | $124,551 |
Drugs they prescribed that Part D paid
$78,879
Pharmacies billed $78,879 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 230) in 2024. At or below the middle of the specialty; the typical optometry clinician is at 0%.
75 generic and 155 brand-name prescriptions · $78,879 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Restasis | 18 | $20,774 | $1,154 |
| Lumigan | 11 | $7,028 | $639 |
| Rocklatan | 12 | $5,418 | $452 |
| Cyclosporine | 12 | $2,746 | $229 |
| Latanoprost | 58 | $472 | $8 |
See all 6 drugs
| Restasis | 18 | $20,774 | $1,154 |
| Lumigan | 11 | $7,028 | $639 |
| Rocklatan | 12 | $5,418 | $452 |
| Cyclosporine | 12 | $2,746 | $229 |
| Latanoprost | 58 | $472 | $8 |
| Timolol Maleate | 19 | $356 | $19 |
Year by year
| 2024 | 230 | 72 | 0% (0) | 67% | $78,879 |
| 2023 | 205 | 75 | 0% (0) | 62% | $67,176 |
| 2022 | 132 | 63 | 0% (0) | 62% | $56,733 |
| 2021 | 56 | 26 | 0% (0) | 64% | $12,241 |
| 2020 | 32 | 15 | 0% (0) | 59% | $8,071 |
| 2019 | 57 | 26 | 0% (0) | 53% | $26,608 |
| 2018 | 64 | 27 | 0% (0) | 50% | $24,406 |
| 2017 | 50 | 25 | 0% (0) | 52% | $8,392 |
| 2016 | 106 | 37 | 0% (0) | 53% | $15,384 |
| 2015 | 26 | 11 | 0% (0) | 65% | $1,799 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 4 drugs
| Restasis | 14 | $19,528 | $1,395 |
| Timolol Maleate | 28 | $959 | $34 |
| Latanoprost | 37 | $684 | $18 |
| Neomycin-Polymyxin-Dexameth | 13 | $296 | $23 |
2022: 3 drugs
| Restasis | 11 | $20,167 | $1,833 |
| Latanoprost | 18 | $328 | $18 |
| Timolol Maleate | 13 | $179 | $14 |
2021: 2 drugs
| Latanoprost | 17 | $543 | $32 |
| Bacitracin-Polymyxin | 12 | $160 | $13 |
2020: 1 drug
| Simbrinza | 13 | $2,202 | $169 |
2019: 2 drugs
| Restasis | 12 | $19,668 | $1,639 |
| Latanoprost | 16 | $381 | $24 |
2018: 1 drug
| Latanoprost | 21 | $447 | $21 |
2016: 2 drugs
| Restasis | 14 | $7,665 | $547 |
| Latanoprost | 38 | $456 | $12 |
Money from drug and device companies
$112 in 2025
| 2025 | 1 | 3 | None | $112 |
| 2024 | 5 | 8 | None | $175 |
| 2023 | 9 | 30 | None | $625 |
| 2022 | 6 | 10 | None | $256 |
| 2021 | 6 | 11 | None | $221 |
| 2020 | 4 | 5 | None | $175 |
| 2019 | 11 | 32 | None | $820 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Biotissue Holdings | None | $112 | 3 payments
|
See all 3 published payments
| Biotissue Holdings | Meals · 2025-06-02 | None | $25 |
| Biotissue Holdings | Meals · 2025-02-27 | None | $62 |
| Biotissue Holdings | Meals · 2025-01-21 | None | $25 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $175
| Biotissue Holdings | None | $64 | 3 payments
|
| Bausch & Lomb Americas | Miebo | $43 | 2 payments
|
| Oyster Point Pharma | Tyrvaya | $25 | 1 payment
|
| ANI Pharmaceuticals | Purified Cortrophin Gel | $22 | 1 payment
|
| Sun Pharmaceutical Industries | Cequa | $22 | 1 payment
|
2023: $625
| Sun Pharmaceutical Industries | Cequa | $180 | 8 payments
|
| Oyster Point Pharma | Tyrvaya | $165 | 10 payments
|
| Bausch & Lomb Americas | Vyzulta | $71 | 3 payments
|
| Novartis Pharmaceuticals | Xiidra | $67 | 3 payments
|
| Sight Sciences | Tearcare System | $51 | 2 payments
|
| Biotissue Holdings | Prokera | $24 | 1 payment
|
| Alcon Vision | Clareon | $24 | 1 payment
|
| ANI Pharmaceuticals | Purified Cortrophin Gel | $22 | 1 payment
|
| Harrow Eye | Iheezo | $21 | 1 payment
|
2022: $256
| Sun Pharmaceutical Industries | Cequa | $87 | 3 payments
|
| Bausch & Lomb Americas | Prolensa | $49 | 2 payments
|
| Dompe US | Oxervate | $44 | 2 payments
|
| Oyster Point Pharma | Tyrvaya | $32 | 1 payment
|
| Abbvie | Vuity | $25 | 1 payment
|
| Kala Pharmaceuticals | Inveltys | $19 | 1 payment
|
2021: $221
| Kala Pharmaceuticals | Inveltys | $49 | 3 payments
|
| Bausch & Lomb a division of Bausch Health US | Prolensa | $46 | 2 payments
|
| Sun Pharmaceutical Industries | Cequa | $40 | 2 payments
|
| Novartis Pharmaceuticals | Xiidra | $35 | 2 payments
|
| Tissuetech | Prokera | $33 | 1 payment
|
| Sight Sciences | Omni(R) Surgical System (US) | $17 | 1 payment
|
2020: $175
| Sun Pharmaceutical Industries | Cequa | $115 | 2 payments
|
| Novartis Pharmaceuticals | Xiidra | $21 | 1 payment
|
| Bausch & Lomb a division of Bausch Health US | Lotemax Sm | $20 | 1 payment
|
| Carl Zeiss Meditec AG | None Specified | $19 | 1 payment
|
2019: $820
| Bausch & Lomb a division of Bausch Health US | Envista | $191 | 11 payments
|
| Allergan | Restasis | $167 | 4 payments
|
| Aerie Pharmaceuticals | Rhopressa | $111 | 1 payment
|
| Shire North American Group | Xiidra | $108 | 5 payments
|
| Dompe US | Oxervate | $81 | 1 payment
|
| Sun Pharmaceutical Industries | Bromsite | $39 | 3 payments
|
| Sight Sciences | Tearcare | $36 | 3 payments
|
| Novartis Pharmaceuticals | Xiidra | $24 | 1 payment
|
| Alcon Vision | Panoptix | $24 | 1 payment
|
| Eyevance Pharmaceuticals | Flarex | $20 | 1 payment
|
| Kala Pharmaceuticals | Inveltys | $20 | 1 payment
|
Professional record
- NPI
- 1912324112
- Licence
- CA 14995California C14995: Deceased
- Trained
- University of California - School of Optometry, 2014
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 152W00000X (152W00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2014-03-25
- NPI last updated
- 2025-05-06
- NPI record certified
- 2025-05-06
This is when the NPI record was last certified, not a medical board exam.